Transforming growth factor ?1-induced cellular heterogeneity in the periosteum of rat parietal bones

Taniguchi, Yasuyuki; Tanaka, Tomoji; Gotoh, Kohsei; Satoh, Ryohei; Inazu, Mizuho

doi:10.1007/bf01321890

Cited by 26 publications

(9 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 However, its effects in vivo were demonstrated to be age-dependent, enhancing osteoblast differentiation only in neonatal but not in adult rats. 28 In our study, PTH induced increases in TGF-b isoforms only in growing rats, while no effects were found in 13-month-old animals. It was recently shown that PTH, besides stimulating several intracellular signaling pathways, also stimulates expression of latent TGF binding protein in rat osteoblastic osteosarcoma cells.…”

Section: Discussioncontrasting

confidence: 52%

Intermittent parathyroid hormone (PTH) treatment and age‐dependent effects on rat cancellous bone and mineral metabolism

Friedl

Turner

Evans

et al. 2007

Journal Orthopaedic Research

View full text Add to dashboard Cite

In recent years, intermittent PTH treatment has been investigated extensively for its efficacy in preventing osteoporotic fractures and to improve fracture healing and implant fixation. Although these tasks concern patients of all ages, very little is known about whether aging impacts the bone anabolic response to PTH. Female Sprague-Dawley rats of 1, 3, and 13 months of age were either treated by hPTH-(1-34) or by vehicle solution (CTR) for 1 week. As main outcome measures, we determined the effects on static and dynamic histomorphometry of cancellous bone. In addition, we measured gene expression in femur and serum parameters reflecting bone turnover and mineral metabolism. There was a profound decrease in bone formation rate (BFR) with aging in CTR rats, whereas PTH treatment resulted in a significant relative 1.5-, 3-, and 4.7-fold increase in BFR, without altering indices of bone resorption. Aging decreased and PTH increased mRNA levels for bone matrix proteins and growth factors in a gene-specific manner. In younger animals, PTHinduced a marked stimulation in the mineral apposition rate with no effect on osteoblast number, whereas the latter was increased in older animals (1.0-, 1.7-, and 3.1-fold). Treatment with PTH in young rats led to a significant increase in trabecular number (1.6-2.6/mm, p < 0.05), whereas older rats demonstrated increases in trabecular thickness only (52.8-77.8 mm, p < 0.001). Although PTH increased bone formation at all ages, we found significant age-related differences in the cellular and molecular mechanisms involved in the bone anabolic response to the hormone. ß

show abstract

Section: Discussioncontrasting

confidence: 52%

Intermittent parathyroid hormone (PTH) treatment and age‐dependent effects on rat cancellous bone and mineral metabolism

Friedl

Turner

Evans

et al. 2007

Journal Orthopaedic Research

View full text Add to dashboard Cite

show abstract

“…Others have shown that in the developing limb, transforming growth factor-p (TGF-P) is first expressed in prechondrogenic condensed mesenchyme and later in the incipient periosteum (30,38). This correlates well with the fact that injections of TGF-P into periosteum stimulate formation of new skeletal tissue (11,22,47). It is therefore conceivable that gene products such as paired and TGF-P may have roles in establishing the complex patterns of syndecan-3 and tenascin-C gene expression described here.…”

Section: Discussionsupporting

confidence: 70%

Expression of syndecan‐3 and tenascin‐C: Possible involvement in periosteum development

Koyama

Shimazu

Leatherman

et al. 1996

Journal Orthopaedic Research

View full text Add to dashboard Cite

The development of cartilaginous elements of long bone during embryogenesis and postnatal bone repair processes is a complex process that involves skeletal cells and surrounding mesenchymal periosteal cells. Relatively little is known of the mechanisms underlying these processes. Previous studies from this and other laboratories have suggested that the extracellular matrix protein tenascin-C is involved in skeletogenesis. Using in situ hybridization and immunofluorescence, we extended those studies by comparing the expression of tenascin-C with that of syndecan-3, which belongs to a family of cell surface receptors with which tenascins are known to interact. We found that syndecan-3 transcripts at first were very abundant in the presumptive periosteum surrounding the diaphysis of early chondrocytic skeletal elements in chick limb. As the elements developed further, syndecan-3 gene expression decreased in the diaphyseal periosteum, whereas it became stronger around the early epiphysis and within the forming articular cells. However, as the diaphyseal periosteum initiated osteogenesis and gave rise to the intramembranous bone collar, syndecan-3 gene expression increased again. At early stages of skeletogenesis: the tenascin-C gene exhibited patterns of expression that were similar to and temporally followed, those of the syndecan-3 gene. At later stages, however, tenascin-C gene expression was markedly reduced during intramembranous osteogenesis around the diaphysis. In addition, although syndecan-3 gene expression was low in osteoblasts and osteocytes located deep into trabecular bone, tenascin-C gene expression remained strong. Thus, tenascin-C and syndecan-3 display distinct temporal and spatial patterns of expression in periosteum and during the development of long bone. Given their multidomain structure and specific patterns of expression, these macromolecules may regulate site-specific skeletal processes, including interactions between developing periosteum and chondrocytes and delineation of the early cartilaginous skeletal elements.

show abstract

“…21 The procedure consisted in solubilizing 0.5 g of recombinant human (rh) TGF-␤ 1 with 5 g of carrier bovine serum albumin (Wako Pharmacal Co., Osaka, Japan) in 12.5 L of 0.5 mM HCl and 12.5 L of phosphate buffered saline (pH 7.4). 3,22 The OCP granules (5 mg) were immersed in the rhTGF-␤ 1 solution, placed in −20°C for 20 min, then vacuum-dried for 1 h. The OCP granules (5 mg) for control were processed in the same way, except that the granules were immersed in 12.5 L of 0.5 mM HCl and 12.5 L of phosphate buffered saline without rhTGF-␤ 1 (Control/ OCP). The combination was performed 12 h before grafting.…”

Section: Preparation Of Ocp and Combined With/without Tgf-␤mentioning

confidence: 99%

Implantation of octacalcium phosphate combined with transforming growth factor-?1 enhances bone repair as well as resorption of the implant in rat skull defects

Kamakura

Sasano

Nakajo

et al. 2001

J. Biomed. Mater. Res.

View full text Add to dashboard Cite

In our previous study, we reported that synthetic octacalcium phosphate (OCP) enhances bone repair if implanted in rat skull defects. We hypothesized that OCP can be used as an effective carrier for transforming growth factor-beta1 (TGF-beta1) to promote bone repair. We designed the present study to investigate histomorphometrically whether combination with recombinant human TGF-beta1 could promote bone repair caused by OCP per se (Control/OCP). A full-thickness standardized trephine defect was made in the rat parietal bone and OCP combined with recombinant human TGF-beta1 (TGF-beta1/OCP) or Control/OCP was implanted into the defect. Four rats from each group were fixed at 2, 4, and 8 weeks after implantation. Histomorphometrical analysis of the percentage of newly formed bone (n-Bone %) and remaining implants (r-Imp %) in the defect was performed. The statistical analysis showed the n-Bone % of TGF-beta1/OCP was significantly higher than that of the Control/OCP in week 4, whereas the r-Imp % of TGF-beta1/OCP was significantly lower than that of the Control/OCP. The present study demonstrated that OCP can be used as an effective carrier for TGF-beta1 and their combination enhances bone repair as well as resorption of the carrier OCP in the early stage of bone formation.

show abstract

Transforming growth factor ?1-induced cellular heterogeneity in the periosteum of rat parietal bones

Cited by 26 publications

References 25 publications

Intermittent parathyroid hormone (PTH) treatment and age‐dependent effects on rat cancellous bone and mineral metabolism

Intermittent parathyroid hormone (PTH) treatment and age‐dependent effects on rat cancellous bone and mineral metabolism

Expression of syndecan‐3 and tenascin‐C: Possible involvement in periosteum development

Implantation of octacalcium phosphate combined with transforming growth factor-?1 enhances bone repair as well as resorption of the implant in rat skull defects

Contact Info

Product

Resources

About